Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia (Q46298030)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia |
scientific article |
Statements
1 reference
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia (English)
1 reference
1 reference
Giuliana Alimena
1 reference
Giovanni Martinelli
1 reference
Michele Baccarani
1 reference
Massimo Breccia
1 reference
Roberto Latagliata
1 reference
Alfonso Zaccaria
1 reference
Francesco Fabbiano
1 reference
Franca Falzetti
1 reference
Franco Mandelli
1 reference
Paola Fazi
1 reference
Simona Iacobelli
1 reference
Maria Teresa Pirrotta
1 reference
Sergio Amadori
1 reference
Monica Morselli
1 reference
Marco Vignetti
1 reference
Marco Sborgia
1 reference
Cecilia Caramatti
1 reference
Anna Candoni
1 reference
Daniele Mattei
1 reference
20 October 2008
1 reference
1 reference
143
1 reference
5
1 reference
681-689
1 reference
Identifiers
1 reference
1 reference